大剂量抗坏血酸用于烧伤休克复苏可能不改善结局
该回顾性病例对照研究纳入2012至2015年烧伤休克复苏患者,比较接受大剂量抗坏血酸(HDAA)者38例与匹配对照42例。两组在年龄、烧伤总面积上无差异,机械通气天数、呼吸机相关性肺炎发生率和死亡率均无显著差异;HDAA组需透析的急性肾衰竭发生率数值上更高,多因素分析比值比为5.4(95%CI 1.1-26)。
要点
- HDAA组与对照组在年龄、烧伤总面积及三度烧伤面积上无差异
- 两组呼吸机相关性肺炎发生率(29% vs 14%,P=.13)和死亡率(26% vs 23%,P=.8)无显著差异
- HDAA组需透析的急性肾衰竭发生率数值上更高(23% vs 7%,P=.06),多因素分析比值比5.4(95%CI 1.1-26)
核心结论
- 大剂量抗坏血酸虽可能减轻烧伤休克复苏期间的炎症和液体需求,但可能不改善机械通气需求、呼吸机相关性肺炎和死亡率等有意义的结局。
研究设计与样本
- 回顾性病例对照研究,2012至2015年,纳入接受HDAA的烧伤休克复苏患者38例,并按年龄和烧伤总面积匹配未接受HDAA的对照42例。
主要发现
- 两组年龄、烧伤总面积及三度烧伤面积无差异。
- 吸入性损伤发生率HDAA组52% vs 对照组36%(P=.17),无显著差异。
- 两组住院天数和机械通气天数相似。
- 呼吸机相关性肺炎发生率HDAA组29% vs 对照组14%(P=.13),无显著差异。
- 死亡率HDAA组26% vs 对照组23%(P=.8),无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High dose ascorbic acid (HDAA) has been touted to ameliorate inflammation and reduce fluid requirements during burn shock resuscitation (BSR). Whether this leads to improved outcomes is not known. The authors' aim for this study was to compare ventilator days, ventilator-associated pneumonia, and mortality between patients who did and did not receive HDAA during BSR.The authors performed a retrospective case control study from 2012 to 2015. They identified 38 patients (HDAA) who received HDAA during BSR. Using age and %TBSA, the authors identified and matched 42 control patients (CTL) who did not receive HDAA for BSR during that same time period. The authors collected data for age, %TBSA, hospital days (LOS), ventilator days (VENT), inhalation injury (INH), ventilator-associated pneumonia (VAP), and mortality (MORT).There were no differences in age and %TBSA or %TBSA of third-degree burn injury between groups. There was no significant difference in the incidence of INH (HDAA-52% vs CTL-36%, P = .17) and the groups had similar LOS and VENT. Additionally, there was no significant difference in VAP incidence (HDAA-29% vs CTL-14%, P = .13) or mortality (HDAA-26% vs CTL-23%, P = .8). HDAA patients had a numerically higher incidence of acute renal failure requiring dialysis (23 vs 7%, P = .06) which was confirmed in a multivariate analysis (odds ratio 5.4; 95% confidence interval 1.1-26). HDAA, while potentially reducing inflammation and fluid requirements during BSR, may not improve any meaningful outcomes such as ventilator requirements, ventilator-associated pneumonia, and mortality.
引用
- Lin J, Falwell S, Greenhalgh D, et al. High-Dose Ascorbic Acid for Burn Shock Resuscitation May Not Improve Outcomes. J Burn Care Res. 2018. PMID: 29931212. doi:10.1093/jbcr/irx030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。